Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Summary 415 million people live with diabetes worldwide, and an estimated 193 million
people have undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients …

5′-Adenosine monophosphate–activated protein kinase (AMPK) is a master regulator of
energy homeostasis in eukaryotes. Despite three decades of investigation, the biological …

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia
together with disturbances in the metabolism of carbohydrates, proteins and fat, which in …

Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …

Background Guidelines have classified patients with acute coronary syndrome (ACS) and
diabetes as a special population, with specific sections presented for the management of …

Diabetes mellitus (DM) is a chronic illness with an increasing global prevalence. More than
537 million cases of diabetes were reported worldwide in 2021, and the number is steadily …

Diabetes mellitus is a complex disorder characterized by insufficient insulin production or
insulin resistance, which results in a lifelong dependence on glucose-lowering drugs for …

Dipeptidyl peptidase IV (DPP-IV) is a new molecular target correlated with the development
of type 2 diabetes. Literature describes the identification of some inhibitory peptides from the …